Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Cash: 2020-2024

Historic Change in Cash for Immuneering (IMRX) over the last 4 years, with Dec 2024 value amounting to -$9.1 million.

  • Immuneering's Change in Cash fell 4.94% to -$9.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$23.3 million, marking a year-over-year decrease of 75.81%. This contributed to the annual value of -$23.3 million for FY2024, which is 75.81% down from last year.
  • Immuneering's Change in Cash amounted to -$9.1 million in Q4 2024, which was up 37.61% from -$14.5 million recorded in Q3 2024.
  • In the past 5 years, Immuneering's Change in Cash registered a high of $56.7 million during Q3 2021, and its lowest value of -$36.0 million during Q3 2023.
  • Over the past 3 years, Immuneering's median Change in Cash value was -$5.2 million (recorded in 2022), while the average stood at -$3.2 million.
  • In the last 5 years, Immuneering's Change in Cash skyrocketed by 1,723.38% in 2021 and then crashed by 212.31% in 2023.
  • Quarterly analysis of 5 years shows Immuneering's Change in Cash stood at $31.5 million in 2020, then tumbled by 201.74% to -$32.0 million in 2021, then spiked by 88.20% to -$3.8 million in 2022, then crashed by 128.37% to -$8.6 million in 2023, then dropped by 4.94% to -$9.1 million in 2024.
  • Its Change in Cash stands at -$9.1 million for Q4 2024, versus -$14.5 million for Q3 2024 and -$6.6 million for Q2 2024.